Pulmonary Vascular Disease News

Pulsed, inhaled nitric oxide at a higher dose was safe and well tolerated, and resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease.

New exploratory endpoint data from the INSPIRE study show improvements after 2 months of treatment with inhaled treprostinil in quality of life, 6-minute walk distance and New York Heart Association functional class.

New data expand the range of pulmonary vascular resistance associated with mortality and heart failure in patients at risk for pulmonary hypertension undergoing right heart catheterization.

Exercise intolerance was common among patients with chronic thromboembolic pulmonary hypertension, or CTEPH, after undergoing pulmonary endarterectomy, despite hemodynamic normalization, according to researchers.

Use of oral add-on selexipag in children was well tolerated, safe and improved pulmonary arterial hypertension outcomes, according to data published in The Journal of Heart and Lung Transplantation.

Patients with acute pulmonary embolism and metabolic syndrome had higher rates of recurrent venous thromboembolism, according to a new study published in Annals of the American Thoracic Society.

Patients with pulmonary arterial hypertension treated in a specialty care center had improved mortality and hospitalization, according to new data published in CHEST.

Dexamethasone did not significantly reduce major complications and mortality at 30 days in infants who underwent cardiac surgery with cardiopulmonary bypass compared with placebo, according to findings from the DECISION trial.

Inhaled treprostinil was well tolerated and significantly improved exercise capacity and other clinical outcomes over 16 weeks in patients with pulmonary hypertension associated with interstitial lung disease, according to results of the INCREASE study.

In the phase 2 PULSAR trial, treatment with sotatercept for 24 weeks resulted in greater reduction in pulmonary vascular resistance than placebo in patients with pulmonary arterial hypertension on stable background therapies.